crane(CR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CR crane

Post-Mkt 04-14 18:50:26 EDT

193.59

-0.20

-0.10%

盘后194.33

+0.74+0.38%

16:19 EDT

High196.07	Low191.63	Vol259.69K
Open194.19	D1 Closing193.79	Amplitude2.29%
Mkt Cap11.15B	Tradable Cap9.44B	Total Shares57.60M
T/O50.48M	T/O Rate0.53%	Tradable Shares48.76M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CR","market":"US","secType":"STK","nameCN":"crane","latestPrice":193.59,"timestamp":1776196800000,"preClose":193.79,"halted":0,"volume":259692,"hourTrading":{"tag":"盘后","latestPrice":194.3344,"preClose":193.59,"latestTime":"16:19 EDT","volume":7295,"amount":1412506.9224,"timestamp":1776197991379,"change":0.7444,"changeRate":0.003845,"amplitude":0.003845},"delay":0,"changeRate":-0.0010320449971618177,"floatShares":48764858,"shares":57596887,"eps":6.247815,"marketStatus":"Post-Mkt","change":-0.2,"latestTime":"04-14 18:50:26 EDT","open":194.19,"high":196.07,"low":191.63,"amount":50479697.2388,"amplitude":0.022911,"askPrice":197.42,"askSize":10,"bidPrice":192,"bidSize":75,"shortable":3,"etf":0,"ttmEps":6.247815,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1776211200000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"NYSE","adjPreClose":193.79,"dividendRate":0.004881,"preHourTrading":{"tag":"盘前","latestPrice":194.57,"preClose":193.79,"latestTime":"08:59 EDT","volume":2,"amount":389.14,"timestamp":1776171588235,"change":0.78,"changeRate":0.004025,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":194.3344,"preClose":193.59,"latestTime":"16:19 EDT","volume":7295,"amount":1412506.9224,"timestamp":1776197991379,"change":0.7444,"changeRate":0.003845,"amplitude":0.003845},"volumeRatio":0.541473,"impliedVol":0.4907,"impliedVolPercentile":0.98},"requestUrl":"/m/hq/s/CR/wiki","defaultTab":"wiki","newsList":[{"id":"2627421074","title":"Crane Is Maintained at Hold by Stifel","url":"https://stock-news.laohu8.com/highlight/detail?id=2627421074","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627421074?lang=en_us&edition=fundamental","pubTime":"2026-04-14 22:23","pubTimestamp":1776176580,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 14, 2026 10:23 ET (14:23 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CR","BK4161","SF","BK4127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627555674","title":"Sirtex Medical's DOORwaY90 Study Demonstrates 100% Local Tumor Control with SIR-Spheres®, Setting a New Benchmark in Y-90 for HCC","url":"https://stock-news.laohu8.com/highlight/detail?id=2627555674","media":"prnewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627555674?lang=en_us&edition=fundamental","pubTime":"2026-04-13 21:00","pubTimestamp":1776085200,"startTime":"0","endTime":"0","summary":"The DOORwaY90 study met its prespecified co-primary endpoints, achieving a best overall response rate  of 99%. WOBURN, Mass., April 13, 2026 /PRNewswire/ --Sirtex Medical , a leading manufacturer of interventional oncology and embolization solutions, today announced landmark 12-month results from the DOORwaY90 study, the first pivotal, prospective, multicenter U.S. trial of Y-90 selective internal radiation therapy  using partition dosimetry in patients with unresectable hepatocellular carcinoma .The DOORwaY90 study met its prespecified co-primary endpoints, demonstrating a 90% complete response  rate and a best overall response rate  of 99%, as assessed by blinded independent central review. All evaluable patients responded to treatment, resulting in 100% local tumor control—one of the highest reported response outcomes in Y-90 therapy. Responses were durable, with 75% lasting beyond six months and a median duration of 295 days, reinforcing the potential of SIR-Spheres Y-90 resin micr","market":"nz","thumbnail":"https://mma.prnewswire.com/media/926923/Sirtex_Medical_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/926923/Sirtex_Medical_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/sirtex-medicals-doorway90-study-demonstrates-100-local-tumor-control-with-sir-spheres-setting-a-new-benchmark-in-y-90-for-hcc-302739680.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CR","BK4006","BK7095","SIR","ORR.AU","BK4161","HCC","USA","ORR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625695893","title":"Crane Company updates financial calendar for first-quarter earnings release and call","url":"https://stock-news.laohu8.com/highlight/detail?id=2625695893","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625695893?lang=en_us&edition=fundamental","pubTime":"2026-04-07 20:30","pubTimestamp":1775565017,"startTime":"0","endTime":"0","summary":"Crane scheduled first-quarter fiscal 2026 earnings release for April 27, 2026 via www.craneco.com.Company set webcast teleconference for April 28, 2026 at 10:00 a.m. ET, accessible in listen-only mode at www.craneco.com.Slide presentation will post on www.craneco.com alongside call materials.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Crane Company published the original content used to generate this news brief via Business Wire  on April 07, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nNDL4bpzHT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CR","BK4161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625677958","title":"Crane Company Announces Date for First Quarter 2026 Earnings Release and Teleconference","url":"https://stock-news.laohu8.com/highlight/detail?id=2625677958","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625677958?lang=en_us&edition=fundamental","pubTime":"2026-04-07 20:30","pubTimestamp":1775565001,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nTUA2DSCKQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4161","CR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623834815","title":"Press Release: Tempest Reports Year End 2025 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2623834815","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623834815?lang=en_us&edition=fundamental","pubTime":"2026-03-30 21:00","pubTimestamp":1774875600,"startTime":"0","endTime":"0","summary":"Completed strategic acquisition of dual-targeting CAR-T assets from Factor Bioscience Inc.Named Matt Angel, Ph.D., Chief Executive Officer & President. \"2025 was a transformative year for Tempest as we strengthened our pipeline with the strategic acquisition of a portfolio of next-generation CAR-T assets,\" said Matt Angel, Ph.D., President and Chief Executive Officer of Tempest. \"The portfolio is already proving potentially fruitful as we reported encouraging early clinical data from our lead CAR-T program, TPST-2003, which is being tested in a Phase 1/2a trial in patients with relapsed or refractory multiple myeloma. The data, which suggests a favorable safety and efficacy profile for TPST-2003, reinforced our belief that this therapy has the potential to differentiate itself from currently approved CAR-T treatments and provide a meaningful option for patients who continue to face limited durable treatment options. We look forward to the potential initiation of a U.S. registrational s","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4230","BK4211","BK4161","BK4195","BK4022","BK4139","CR","PFS","CAR","TPST"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623731207","title":"Journal of Urology Publishes ENVISION Trial Results Showing 72.2% 24-Month Duration of Response with ZUSDURI","url":"https://stock-news.laohu8.com/highlight/detail?id=2623731207","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623731207?lang=en_us&edition=fundamental","pubTime":"2026-03-30 20:00","pubTimestamp":1774872000,"startTime":"0","endTime":"0","summary":"72.2% Probability of Remaining Event-Free at 24 Months by Kaplan-Meier Analysis After Achieving Complete Response at Three Months (79.6%) PRINCETON, N.J., March  30, 2026 (GLOBE NEWSWIRE) -- UroGen Ph","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/30/3264559/0/en/Journal-of-Urology-Publishes-ENVISION-Trial-Results-Showing-72-2-24-Month-Duration-of-Response-with-ZUSDURI.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4161","CR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622154866","title":"ImmunityBio Lead Bladder Cancer Drug Trial Clears Power Check","url":"https://stock-news.laohu8.com/highlight/detail?id=2622154866","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622154866?lang=en_us&edition=fundamental","pubTime":"2026-03-26 22:04","pubTimestamp":1774533840,"startTime":"0","endTime":"0","summary":"ImmunityBio stock dips despite Anktiva trial validation, FDA ad warning, and bullish analyst targets amid strong year-to-date gains.","market":"nz","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/03/26/San-Diego--Ca--Usa---July-9--2022-Immuni.jpeg?optimize=medium&dpr=2&auto=webp&width=260","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/03/26/San-Diego--Ca--Usa---July-9--2022-Immuni.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/news/health-care/26/03/51482773/immunitybio-lead-bladder-cancer-drug-trial-clears-power-check","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/26/03/51482773/immunitybio-lead-bladder-cancer-drug-trial-clears-power-check","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["CR","BK4234","IBRX","PW","BCG","BK4139","BK4084","BK4135","BK4161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622852318","title":"Medicus Pharma Business Update Call to Highlight 80% Overall Response Rate (ORR) in Phase 2 SkinJect Study and Agentic AI-enabled Drug Development Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2622852318","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622852318?lang=en_us&edition=fundamental","pubTime":"2026-03-26 19:30","pubTimestamp":1774524600,"startTime":"0","endTime":"0","summary":"200g Cohort at Day 57 Dataset suggests majority of treated Lesions may Avoid Surgery as Company targets larger unmet medical need in Non-melanoma Skin CancerPHILADELPHIA, March  26, 2026 (GLOBE NEWSWI","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/26/3262893/0/en/Medicus-Pharma-Business-Update-Call-to-Highlight-80-Overall-Response-Rate-ORR-in-Phase-2-SkinJect-Study-and-Agentic-AI-enabled-Drug-Development-Plan.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4161","BK4139","BK4215","BK4023","BCC","BK4213","ORR","PD","LU1169589451.USD","AIPO","LU1169590202.USD","CR","MDCX","MNA","BK4567","CHAT","PR","AGIX","CSR","BK4104"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622047415","title":"Do Macro Shocks Reveal Hidden Cyclicality In Crane (CR)’s Specialized Technology Story?","url":"https://stock-news.laohu8.com/highlight/detail?id=2622047415","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622047415?lang=en_us&edition=fundamental","pubTime":"2026-03-25 14:04","pubTimestamp":1774418692,"startTime":"0","endTime":"0","summary":"Earlier this week, specialized technology company Crane NXT (NYSE:CXT) saw its shares move alongside other industrial and technology names after reports of easing U.S.-Iran tensions pushed oil prices lower and lifted broader market sentiment.\nThis reaction highlights how Crane NXT’s trading can be influenced by macro-geopolitical developments and commodity price shifts, even though its core business is focused on specialized industrial technologies.\nWith improving geopolitical sentiment...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/3072000-choice2-main-header/1585186655182","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/3072000-choice2-main-header/1585186655182"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/capital-goods/nyse-cr/crane/news/do-macro-shocks-reveal-hidden-cyclicality-in-crane-crs-speci","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/capital-goods/nyse-cr/crane/news/do-macro-shocks-reveal-hidden-cyclicality-in-crane-crs-speci","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CXT","LU0757428866.USD","LU1815336091.USD","CR","BK4157","BK4161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621706487","title":"Amplia Therapeutics Reports Four Additional Complete Responses and Improved Overall Survival Data in Accent Pancreatic Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2621706487","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621706487?lang=en_us&edition=fundamental","pubTime":"2026-03-23 20:45","pubTimestamp":1774269900,"startTime":"0","endTime":"0","summary":"HIGHLIGHTS Formal centralized and independent analysis of the clinical response data from the ACCENT trial has been undertaken and updated analysis provided to the CompanyThe data confirm that five (5","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/23/3260403/0/en/Amplia-Therapeutics-Reports-Four-Additional-Complete-Responses-and-Improved-Overall-Survival-Data-in-Accent-Pancreatic-Cancer-Trial.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4211","ORR","BK4195","BK4161","BK4007","BK4097","BK4213","CR","OS","INNMF","PFS","PR","LENZ","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620766332","title":"Press Release: Relmada Therapeutics Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2620766332","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620766332?lang=en_us&edition=fundamental","pubTime":"2026-03-20 04:01","pubTimestamp":1773950460,"startTime":"0","endTime":"0","summary":"-- Positive 12-month Phase 2 data for NDV-01 in non-muscle invasive bladder. cancer  demonstrated a 95% complete response  rate at any time. and a durable 76% CR rate at 12 months, with favorable safety profile. through 2029, including completion of the NDV-01 RESCUE program. \"NDV-01's compelling efficacy, durability, and favorable safety profile, combined with operational ease-of-use are the cornerstone of its differentiated product profile and best-in-class potential,\" said Raj S. Pruthi, MD, Chief Medical Officer-Oncology of Relmada Therapeutics. \"We continue to be encouraged by the high response rates and durable clinical benefit observed through 12 months, including in the BCG-unresponsive population, alongside a favorable safety profile with no >= Grade 3 treatment-related adverse events and no treatment-related discontinuations. Our clinical program builds on the urologic oncology community's comfort with conventional Gem/Doce's efficacy and safety profile with a sustained relea","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1861220207.SGD","LU1791807156.HKD","DFS","BK4161","BK4539","CR","BK4166","BK4139","LENZ","LU0106831901.USD","LU1668664300.SGD","LU2360107671.USD","RLMD","BK4007","LU1861217088.USD","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620225777","title":"Moleculin Reports Full Year 2025 Financial Results and Confirms Highly Anticipated 45-Patient Interim Data Unblinding in Pivotal MIRACLE Trial On Track for Mid-2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2620225777","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620225777?lang=en_us&edition=fundamental","pubTime":"2026-03-19 20:36","pubTimestamp":1773923760,"startTime":"0","endTime":"0","summary":"Miracle Trial Preliminary Blinded CRc Rate of 40% in First 30 Patients Suggests Encouraging Early Results in Relapsed/Refractory AML HOUSTON, March  19, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/19/3259011/0/en/Moleculin-Reports-Full-Year-2025-Financial-Results-and-Confirms-Highly-Anticipated-45-Patient-Interim-Data-Unblinding-in-Pivotal-MIRACLE-Trial-On-Track-for-Mid-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4161","CR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619191297","title":"Crane Company publishes 2025 annual report, net sales rise 8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2619191297","media":"Reuters","labels":["executive","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619191297?lang=en_us&edition=fundamental","pubTime":"2026-03-13 19:43","pubTimestamp":1773402212,"startTime":"0","endTime":"0","summary":"Crane reported 2025 sales growth in Aerospace and Process Flow, supported by defense demand and a commercial aerospace production ramp-up. The Aerospace and Advanced Technologies segment posted a 12% sales increase and ended the year with backlog of just over USD 1 billion. Process Flow Technologies reported a record segment operating margin of 21% and cited contributions from the Cryoworks and Technifab acquisitions. The company said it completed acquisitions of Druck, Panametrics, and Reuter Stokes from Baker Hughes, and announced the planned acquisition of optek-Danulat. Crane said CEO Max Mitchell plans to hand the CEO role to COO Alex Alcala at the annual shareholder meeting, with Mitchell expected to serve as Executive Chairman during the transition.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nNDL4B2CH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1261432733.SGD","LU0353189680.USD","LU0157215616.USD","CR","LU0149725797.USD","LU1153585028.USD","LU1066051498.USD","LU0251142724.SGD","LU1280957306.USD","LU1093756168.USD","BK4585","LU0640476718.USD","LU0868494617.USD","BK4543","LU0154245673.USD","LU1974910355.USD","BKR","LU1988902786.USD","LU2264538146.SGD","LU0353189763.USD","LU2168564065.EUR","LU0354030511.USD","GE","LU1066051225.USD","BK4566","BK4501","LU2168563687.JPY","LU1119994496.HKD","LU0820561909.HKD","LU0689472784.USD","LU1066053197.SGD","LU0154245756.USD","LU1917777945.USD","LU0820562030.AUD","LU0742534661.SGD","LU0820561818.USD","LU2463526074.USD","LU0943347566.SGD","BK4187","LU2756315318.SGD","LU1551013342.USD","LU2023250843.SGD","LU2543165471.USD","LU1084165304.USD","LU1366192091.USD","LU0077335932.USD","IE0002270589.USD","LU1066051811.HKD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619195719","title":"Crane Company announces annual stockholders meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2619195719","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619195719?lang=en_us&edition=fundamental","pubTime":"2026-03-13 18:32","pubTimestamp":1773397970,"startTime":"0","endTime":"0","summary":"Crane will hold its annual meeting of stockholders on April 27, 2026 in Old Greenwich, Connecticut. Stockholders will vote on the election of nine directors to serve one-year terms until the 2027 annual meeting. The meeting agenda also includes a proposal to ratify Deloitte & Touche as independent auditor for 2026. Stockholders will also cast a non-binding advisory vote on executive compensation.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Crane Company published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 13, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nNDL7tXm7T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4161","CR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618306889","title":"Protara Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2618306889","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618306889?lang=en_us&edition=fundamental","pubTime":"2026-03-10 20:00","pubTimestamp":1773144000,"startTime":"0","endTime":"0","summary":"Reported interim data from ADVANCED-2 trial in non-muscle invasive bladder cancer (NMIBC); TARA-002 demonstrated 68% complete response rate at six months in BCG-Unresponsive patients Company expects t","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/10/3252699/0/en/Protara-Therapeutics-Announces-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Provides-a-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCG","BK4007","LENZ","IFN","BK4523","BK4139","BK4161","CR","BK4539","BK4135"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618640488","title":"Press Release: enGene Reports First Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2618640488","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618640488?lang=en_us&edition=fundamental","pubTime":"2026-03-09 19:00","pubTimestamp":1773054000,"startTime":"0","endTime":"0","summary":"LEGEND pivotal cohort update planned for a spring 2026 medical conference. 12-month complete response data from LEGEND pivotal cohort expected in 2H 2026. Biologics License Application  submission for detalimogene planned for 2H 2026. Cash and marketable securities of $312.5 million expected to provide cash runway into 2H 2028. enGene Holdings Inc. , a clinical-stage, non-viral genetic medicines company, today announced its financial results for the first quarter ended January 31, 2026, and provided a business update.\"As data from LEGEND's pivotal cohort in high-risk, BCG-unresponsive NMIBC continues to mature, we look forward to providing an update at a spring medical conference,\" said Ron Cooper, President and Chief Executive Officer, enGene. \"On the heels of our successful November follow-on offering, we entered 2026 in a position of financial strength and ready to execute. With RMAT and CDRP designations for detalimogene, we are in active dialogue with the FDA to ensure regulatory ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2237443895.HKD","LU1363072403.SGD","LU2237443622.USD","TRAE","BCG","LU0882574139.USD","BK4139","HTGC","LU0170899867.USD","DDX","LU2746668461.USD","IE00BHPRN162.USD","CMC","BK4585","LU0971096721.USD","LU2237443382.USD","BK4588","LU2746668974.SGD","IE00B1BXHZ80.USD","BK4161","ENGN","CR","BK4135","R","LABU","LU2237443978.SGD","IE00BKVL7J92.USD","IE00BFXG1179.USD","LU2237443549.SGD","LU2237443465.HKD","BK4232","LU0267386448.USD","BK4022","LU0149725797.USD","IE00BZ1G4Q59.USD","BK4006"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618064029","title":"Relmada Therapeutics Reports 12-Month Phase 2 Interim Data for NDV-01 in Non-Muscle Invasive Bladder Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2618064029","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618064029?lang=en_us&edition=fundamental","pubTime":"2026-03-09 19:00","pubTimestamp":1773054000,"startTime":"0","endTime":"0","summary":"Durable 76% complete response (CR) rate at 12 months with 95% CR rate at any time in high-risk NMIBCBCG-unresponsive patients achieved an 80% CR rate at 12 months and 94% CR rate at any time Tolerabil","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/09/3251681/0/en/Relmada-Therapeutics-Reports-12-Month-Phase-2-Interim-Data-for-NDV-01-in-Non-Muscle-Invasive-Bladder-Cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCG","LU1861220207.SGD","BK4195","BK4161","CR","LU0106831901.USD","TRAE","BK4135","LU2360107671.USD","LU1668664300.SGD","BK4588","BK4139","DFS","BK4585","BK4007","BK4166","LU1791807156.HKD","LU1861217088.USD","PFS","BK4211","LENZ","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617979542","title":"Medicus Pharma Reports Positive Phase 2 SKNJCT-003 Topline Data Observing 73% Clinical Clearance and 40% Histological Clearance (CR) at Day 57 in 200μg Cohort","url":"https://stock-news.laohu8.com/highlight/detail?id=2617979542","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617979542?lang=en_us&edition=fundamental","pubTime":"2026-03-05 20:30","pubTimestamp":1772713800,"startTime":"0","endTime":"0","summary":"The Company is expected to finalize the Clinical Study Report (CSR) in Q2 2026 to support planned end of Phase 2 (EOP2) meeting with the FDAPHILADELPHIA, March  05, 2026  (GLOBE NEWSWIRE) -- Medicus P","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/05/3250045/0/en/Medicus-Pharma-Reports-Positive-Phase-2-SKNJCT-003-Topline-Data-Observing-73-Clinical-Clearance-and-40-Histological-Clearance-CR-at-Day-57-in-200%CE%BCg-Cohort.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4215","LU1496350171.SGD","LU2417539215.USD","LU0882574139.USD","LU1718418525.SGD","LU0077335932.USD","LU1935043023.USD","LU2237443382.USD","LU0149725797.USD","LU1066053197.SGD","BK4139","LU0053666078.USD","LU1066051811.HKD","LU1674673428.USD","LU2237443549.SGD","LU1778281490.HKD","LU2083900584.USD","BCC","APC","MDCX","LU0170899867.USD","LU1366192091.USD","LU1935043536.SGD","LU1935042215.USD","LU1066051498.USD","LU1674673691.USD","LU1935042488.USD","LU2236285917.USD","LU2420271590.USD","LU1066051225.USD","CR","LU1935042991.SGD","CSR","BK4567","LU0786609619.USD","LU0157215616.USD","BK4161","LU0314104364.USD","LU1366333091.USD","LU2456880835.USD","MNA","BK4214","LU2237443978.SGD","BK4104","LU2237443622.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614865082","title":"Press Release: ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31st, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2614865082","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614865082?lang=en_us&edition=fundamental","pubTime":"2026-02-28 01:29","pubTimestamp":1772213340,"startTime":"0","endTime":"0","summary":"-- Strong cash position at year-end 2025: $33.3 million . --    Appointed renowned Rolando Gutierrez-Esteinou, M.D.        --    Seven ongoing oncology trials, with six sponsored by. as new CMO for CNS                                      the NCI or top-tier U.S. institutions. --    Preparing protocol resubmission to incorporate FDA         --    Positive data in 1L AML unfit patients presented at. guidance on Phase III PORTICO-2 trial in aggression                       ASH with 100% ORR . in BPD                               --    Positive data in R/R FLT3+ AML presented at ASH; 67%. into additional EU countries                    --    Initiated enrollment in new Phase Ib trial in small. --    Finalizing preparations for new Phase II trial in                   cell lung cancer in combination with ICI and. aggression in autism spectrum disorder as a part of                                  radiotherapy. the IPCEI EU Grant in personalized medicine             --    Continued momentum ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4561","SCD","BK4097","BK4109","BK4161","BK4581","BK4590","BK4585","EMA","BK4081","CR","ET","NCI","ASH","OS","HSCT","ORR","LU2463526074.USD","BK4202","BK4144","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614859948","title":"ZUSDURI™ Achieves Durable Complete Responses Across EORTC Risk Groups in Patients with Recurrent LG-IR-NMIBC","url":"https://stock-news.laohu8.com/highlight/detail?id=2614859948","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614859948?lang=en_us&edition=fundamental","pubTime":"2026-02-27 21:30","pubTimestamp":1772199000,"startTime":"0","endTime":"0","summary":" EORTC Recurrence Score Analysis from the Pivotal ENVISION Trial to be Presented at the 2026 American Society of Clinical Oncology’s Genitourinary Cancers Symposium (ASCO-GU 2026) PRINCETON, N.J., Feb","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/27/3246510/0/en/ZUSDURI-Achieves-Durable-Complete-Responses-Across-EORTC-Risk-Groups-in-Patients-with-Recurrent-LG-IR-NMIBC.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1978683503.SGD","IR","BK4161","BK4588","BK4585","LU0124384867.USD","SG9999001440.SGD","CR","LU0256863902.USD","LU0417517546.SGD","LU0256863811.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cranenxt.com","stockEarnings":[{"period":"1week","weight":0.1219},{"period":"1month","weight":0.1318},{"period":"3month","weight":-0.0534},{"period":"6month","weight":0.0718},{"period":"1year","weight":0.3755},{"period":"ytd","weight":0.0508}],"compareEarnings":[{"period":"1week","weight":0.0412},{"period":"1month","weight":0.036},{"period":"3month","weight":-0.0111},{"period":"6month","weight":0.0315},{"period":"1year","weight":0.285},{"period":"ytd","weight":0.0061}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Crane NXT, Co. focuses on payment and merchandising technologies. It indents to offer electronic equipment and associated software leveraging extensive, and proprietary core capabilities, including payment verification and authentication, as well as automation solutions, field service solutions, remote diagnostics, and productivity enhancing software solutions. The company is based in Stamford, Connecticut.","yearOnYearQuotes":[{"month":1,"riseRate":0.543478,"avgChangeRate":0.020828},{"month":2,"riseRate":0.717391,"avgChangeRate":0.036902},{"month":3,"riseRate":0.565217,"avgChangeRate":0.013749},{"month":4,"riseRate":0.617021,"avgChangeRate":0.005313},{"month":5,"riseRate":0.630435,"avgChangeRate":0.008709},{"month":6,"riseRate":0.586957,"avgChangeRate":0.005131},{"month":7,"riseRate":0.586957,"avgChangeRate":0.004401},{"month":8,"riseRate":0.347826,"avgChangeRate":-0.009516},{"month":9,"riseRate":0.369565,"avgChangeRate":-0.022666},{"month":10,"riseRate":0.586957,"avgChangeRate":0.009396},{"month":11,"riseRate":0.543478,"avgChangeRate":0.025826},{"month":12,"riseRate":0.608696,"avgChangeRate":0.018097}],"exchange":"NYSE","name":"crane","nameEN":"crane"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"crane(CR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest crane(CR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"crane,CR,crane股票,crane股票老虎,crane股票老虎国际,crane行情,crane股票行情,crane股价,crane股市,crane股票价格,crane股票交易,crane股票购买,crane股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"crane(CR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest crane(CR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}